Intensified Rituximab, Methotrexate, Procarbazine, and Cytarabine (R-MPVA) Regimen With Sequential Addition of Etoposide and Ifosfamide for Newly Diagnosed Primary CNS Lymphoma Patients Aged Between 60 and 70 Years: An LOC Network Study.
Intensive chemotherapy improves survival in older patients with brain lymphoma, though longer follow-up is needed to confirm these encouraging signals.
An intensified R-MPVA regimen with sequential addition of etoposide and ifosfamide achieved 81.3% complete or unconfirmed complete response rate after induction in 60-70-year-old primary CNS lymphoma patients from the LOC network. At follow-up, 3-year event-free survival was 40.2% and overall survival 63.2%, improving upon historical R-MPVA response rates despite the limitations of a retrospective single-arm design.
What the study was
- Study design
- retrospective cohort study with historical comparison
- Population
- Primary CNS lymphoma patients aged 60-70 years, LOC network
- Category
- Treatment Innovation
- Maturity
- Validated
- Journal
- Hematological oncology
Why it surfaced
Addresses a relevant clinical challenge (PCNSL in older adults 60-70); intensified regimen shows improved CR rates versus historical controls from LOC network; small single-institution cohort with historical comparison limits generalizability.
A plain-language summary of published research — not medical advice. Talk to a clinician about your own care.